

## BOARD MEETING

19 March 2009  
Item No 09/03/18

<b>Performance Report</b>	
<b>1. Introduction/ Summary of Scheme/Report</b>	
<p>The purpose of this paper is to provide the Board with an overview of the PCTs Performance via the following:  Appendix 1: Performance scorecard  Appendix 2: Performance exception report</p>	
<b>2. Implications and Risks</b>	
<i>Will there be a significant impact on patients or patient care?</i>	<i>No negative impact</i>
<i>Are there any financial implications to implementing this item?</i>	<i>No additional implications</i>
<i>Will there be an impact on Equality, Diversity or Human Rights?</i>	<i>No</i>
<i>Does this item form an essential part of quality or performance standards e.g. Healthcare Commission, NHS Litigation Authority? If yes, detail which standard.</i>	<i>Yes, HCC</i>
<b>3. Recommendation</b>	
The Board is requested to receive and note the current performance.	
<b>4. Submitted by</b>	
<b>Author:</b>	Julie Humphries
<b>Title:</b>	Head of Performance
<b>Sponsoring Director:</b>	Tom Hunt, Director of Finance & Corporate Services
<b>Date:</b>	March 2009
<b>5. Purpose of the Paper</b>	
Information sharing <input checked="" type="checkbox"/>	Development/discussion <input type="checkbox"/>
	Decision/action <input type="checkbox"/>



## Performance Update

### 1. Introduction

This paper sets out the latest performance scorecard (appendix 1). Where there is a current or forecasted risk to successful delivery, the accompanying exception report (appendix 2) offers further insight into the measured performance, what is blocking delivery and actions planned for the next six months and provides an update on timescales for the Annual Health Check prediction process for 2008/09.

### 2. Implications and Risks

The performance measures reported in each of the Appendices are an essential part of the PCT's performance standards. In general the PCT is exhibiting good and improving performance, however MRSA, C. difficile and A&E are the main risk areas with an increased level of scrutiny around the delivery of 18 weeks at specialty levels.

Although new initiatives have been introduced to improve dental performance, this clearly needs to be closely monitored.

### 3. Recommendations

The board is requested to receive and consider the current performance and to particularly note further escalation around MRSA and A&E performance.

### 4. Sponsor Director

Tom Hunt, Director of Finance & Corporate Services

#### Purpose of the Paper

Information sharing       Development/discussion       Decision/action

Version	Date	Summary	Owners Name	Approved
1.0	6 Mar 2009		J Humphries	